Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors

Molecular Pharmacology

Volumn 78, Issue 4, 2010, Pages 577-587

  Desmoulin, Sita Kugel ^a   Wang, Yiqiang ^d   Wu, Jianmei ^b   Stout, Mark ^c   Hou, Zhanjun ^b   Fulterer, Andreas ^e   Chang, Min Hwang ^e   Romero, Michael F ^e   Cherian, Christina ^b   Gangjee, Aleem ^d   Matherly, Larry H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d DUQUESNE UNIVERSITY   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENOSINE; FOLIC ACID ANTAGONIST; N [4 [3 (2 AMINO 4 OXO 4,7 DIHYDRO 3H PYRROLO[2,3 D]PYRIMIDIN 6 YL)PROPYL]BENZOYL]GLUTAMIC ACID; N [4 [4 (2 AMINO 4 OXO 4,7 DIHYDRO 3H PYRROLO[2,3 D]PYRIMIDIN 6 YL)BUTYL]BENZOYL]GLUTAMIC ACID; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROTON COUPLED FOLATE TRANSPORTER; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; SMALL CYTOPLASMIC RNA; UNCLASSIFIED DRUG; VITAMIN BINDING PROTEIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; GROWTH INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLO(2,3-D)PYRIMIDINE; SLC46A1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CHO CELL; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; OOCYTE; PH; PRIORITY JOURNAL; PURINE SYNTHESIS; SOLID TUMOR; XENOPUS LAEVIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; CHO CELL LINE; COMPARATIVE STUDY; CRICETULUS; DRUG DELIVERY SYSTEM; FEMALE; HAMSTER; HELA CELL LINE; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID ANTAGONISTS; GROWTH INHIBITORS; HELA CELLS; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; PROTON-COUPLED FOLATE TRANSPORTER; PURINES; PYRIMIDINES; PYRROLES; XENOPUS LAEVIS;

EID: 77957224999     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065896     Document Type: Article

References (45)

1. Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26:153-181.
2. Beardsley GP, Moroson BA, Taylor EC, and Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328-333.
3. Bronder JL and Moran RG (2002) Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Cancer Res 62:5236-5241.
4. Chattopadhyay S, Moran RG, and Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404-417.
5. Deng Y, Wang Y, Cherian C, Hou Z, Buck SA, Matherly LH, and Gangjee A (2008) Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. J Med Chem 51:5052-5063.
6. Deng Y, Zhou X, Kugel Desmoulin S, Wu J, Cherian C, Hou Z, Matherly LH, and Gangjee A (2009) Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. J Med Chem 52:2940-2951.
7. Elnakat H and Ratnam M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56:1067-1084.
8. Farber S and Diamond LK (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238:787-793.
9. Flintoff WF and Nagainis CR (1983) Transport of methotrexate in Chinese hamster ovary cells: a mutant defective in methotrexate uptake and cell binding. Arch Biochem Biophys 223:433-440.
10. Fry DW, Yalowich JC, and Goldman ID (1982) Rapid formation of poly-gammaglutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem 257:1890-1896.
11. Gangjee A, Zeng Y, McGuire JJ, Mehraein F, and Kisliuk RL (2004) Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates. J Med Chem 47:6893-6901.
12. Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, et al. (2005) BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 65:11721-11728.
13. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, and Hediger MA (1997) Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388:482-488. (Pubitemid 27328927)
14. Helmlinger G, Yuan F, Dellian M, and Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3:177-182. (Pubitemid 27064702)
15. Hilgenbrink AR and Low PS (2005) Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94:2135-2146. (Pubitemid 41665275)
16. Huang D, Zhang Y, and Chen X (2003) Analysis of intracellular nucleoside triphosphate levels in normal and tumor cell lines by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 784:101-109. (Pubitemid 36009345)
17. Hughes LR, Stephens TC, Boyle FT and Jackman AL (1999) Raltitrexed (Tomudex), a highly polyglutamatable antifolate thymidylate synthase inhibitor, in Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL ed) pp 147-165, Humana Press, Inc., Totowa, NJ.
18. Illei PB, Rusch VW, Zakowski MF, and Ladanyi M (2003) Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9:2108-2113.
19. Kugel Desmoulin S, Wang Y, Tait L, Hou Z, Cherian C, Gangjee A, and Matherly LH (2010) Expression profiling of the major folate facilitative transporters in human tumors and normal tissues (Abstract). Am Assoc Cancer Res 51:1103.
20. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
21. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
22. 2+ transport and uncoupled fluxes. Pflugers Arch 451:544-558.
23. Matherly LH, Hou Z, and Deng Y (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26:111-128.
24. Matsudaira P (1987) Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem 262:10035-10038.
25. Mendelsohn LG, Worzalla JF and Walling JM (1999) Preclinical and clinical evaluation of the glycinamide ribonucleotide formyltransferase inhibitors lometrexol and LY309887, in Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL ed) pp 261-280, Humana Press, Inc., Totowa, NJ.
26. Monahan BP and Allegra CJ (2006) Antifolates, in Cancer Chemotherapy and Biotherapy (Chabner BA, Longo DL eds) pp 91-124, Lippincott Williams & Wilkins, Philadelphia, PA.
27. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, and Yuasa H (2007) Functional characterization of human proton-coupled folate transporter/ heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther 322:469-476.
28. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, and Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917-928.
29. Racanelli AC, Rothbart SB, Heyer CL, and Moran RG (2009) Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69:5467-5474.
30. Raghunand N, Altbach MI, van Sluis R, Baggett B, Taylor CW, Bhujwalla ZM, and Gillies RJ (1999) Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol 57:309-312.
31. Salazar MD and Ratnam M (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26:141-152.
32. Schmid M, Malicki D, Nobori T, Rosenbach MD, Campbell K, Carson DA, and Carrera CJ (1998) Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 17:2669-2675.
33. Smith GK, Bigley JW, Dev IK, Duch DS, Ferone R, and Pendergast W (1999) A Potent, Noncompetitive Thymidylate Synthase Inhibitor - Preclinical and Preliminary Clinical Studies, Humana Press, Inc., Totowa, NJ.
34. Smith SG, Lehman NL, and Moran RG (1993) Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res 53:5697-5706.
35. Stokstad ELR (1990) Historical perspective on key advances in the biochemistry and physiology of folates, in Folic Acid Metabolism in Health and Disease (Picciano MF, Stokstad EL, Spector R eds) pp 1-21, Wiley-Liss, New York.
36. Unal ES, Zhao R, Chang MH, Fiser A, Romero MF, and Goldman ID (2009) The functional roles of the His247 and His281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1. J Biol Chem 284:17846-17857.
37. Wang L, Cherian C, Desmoulin SK, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly LH, et al. (2010) Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. J Med Chem 53:1306-1318.
38. Wong SC, Proefke SA, Bhushan A, and Matherly LH (1995) Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 270: 17468-17475.
39. Zain JM and Marchi E (2010) Pralatrexate - from bench to bedside. Drugs Today (Barc) 46:91-99.
40. Zhao R, Gao F, Hanscom M, and Goldman ID (2004a) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718-727.
41. Zhao R and Goldman ID (2003) Resistance to antifolates. Oncogene 22:7431-7457.
42. Zhao R and Goldman ID (2007) The molecular identity and characterization of a Proton-coupled Folate Transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev 26:129-139.
43. Zhao R, Hanscom M, Chattopadhyay S, and Goldman ID (2004b) Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway. Cancer Res 64:3313-3319. (Pubitemid 38581438)
44. Zhao R, Matherly LH, and Goldman ID (2009) Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11:e4.
45. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, and Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74:854-862.